567
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Longitudinal analysis of healthcare costs: a case study of patients with major depressive disorder treated with duloxetine

, , , &
Pages 623-632 | Accepted 18 Feb 2013, Published online: 05 Mar 2013

References

  • Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602
  • Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
  • Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002;36:383-90
  • Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15
  • Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70
  • Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31
  • Eli Lilly and Company. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2012
  • Cui Z, Faries DE, Zhao Y, et al. Trajectory analysis of healthcare costs for patients with major depressive disorder treated with high doses of duloxetine. J Med Econ 2011;14:662-72
  • Liu X, Cui Z, Niu L, et al. Dosing patterns for duloxetine and predictors of high-dose prescriptions in patients with major depressive disorder: analysis from a United States third-party payer perspective. Clin Ther 2011;33:1726-38
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
  • Magee L. R2 measures based on Wald and likelihood ratio joint significance tests. Am Stat 1990;44:250-3

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.